Methotrexate Pause Enhances Vaccine Immunity Against Omicron Methotrexate Pause Enhances Vaccine Immunity Against Omicron
Researchers in Germany report a 10-day post-vaccination hold on methotrexate boosts immunity against Omicron without compromising safety or risk of disease flares.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 20, 2022 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Isotretinoin, Methotrexate Prescribing Concerns Post-Roe v. Wade Isotretinoin, Methotrexate Prescribing Concerns Post-Roe v. Wade
With abortion banned or greatly restricted in many states, dermatologists who prescribe isotretinoin and methotrexate said they are anxious about the future.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 13, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
MTX to Increase Response in Gout Receiving Pegloticase MTX to Increase Response in Gout Receiving Pegloticase
Might the addition of methotrexate help increase pegloticase treatment response in patients with uncontrolled gout?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Clinical Predictors of Methotrexate Response in RA Patients Clinical Predictors of Methotrexate Response in RA Patients
Could certain factors determine treatment response to methotrexate in rheumatoid arthritis patients? A new study uses a machine learning approach to identify potential predictors.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Data Now Out for Pegloticase-MTX Combo Gout Treatment
(MedPage Today) -- Full results from the so-called MIRROR trial have now been published and suggest the FDA made the right decision this summer to approve methotrexate as an add-on to pegloticase (Krystexxa) for patients with uncontrolled gout... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 16, 2022 Category: Primary Care Source Type: news
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Olokizumab Proves Noninferior to Adalimumab for RA Olokizumab Proves Noninferior to Adalimumab for RA
The manufacturer of olokizumab is expected to file for approval in the United States early next year, and the drug could add a new option for patients for whom methotrexate alone doesn ' t work.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Olokizumab Tops Placebo for RA Patients Receiving Methotrexate
THURSDAY, Aug. 25, 2022 -- Olokizumab is superior to placebo and noninferior to adalimumab in patients with rheumatoid arthritis receiving maintenance methotrexate, according to a study published in the Aug. 25 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 25, 2022 Category: Pharmaceuticals Source Type: news
Novel IL-6 Blocker Matches Humira in Rheumatoid Arthritis
(MedPage Today) -- A new type of anti-interleukin-6 (IL-6) biologic called olokizumab was as effective as adalimumab (Humira) in rheumatoid arthritis patients who needed a step up from methotrexate monotherapy, results from a phase III trial indicated... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 25, 2022 Category: Rheumatology Source Type: news
S2 Episode 3: Treating Psoriatic Arthritis With Methotrexate and csDMARDs S2 Episode 3: Treating Psoriatic Arthritis With Methotrexate and csDMARDs
Drs Stanley Cohen and Caylib Durand discuss the treatment paradigm for psoriatic arthritis and the role of methotrexate and other conventional synthetic disease-modifying antirheumatic drugs.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news
Abortion Laws Deny Treatments Needed for Autoimmune Disease Abortion Laws Deny Treatments Needed for Autoimmune Disease
Methotrexate, a first-line treatment for autoimmune diseases, is being denied to some patients since SCOTUS overturned Roe v Wade.Medscape Blogs (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - July 21, 2022 Category: Infectious Diseases Tags: Infectious Diseases Blog Source Type: news
Methotrexate Could Reduce the Risk for Retinal Redetachment Methotrexate Could Reduce the Risk for Retinal Redetachment
Intravitreal injections with methotrexate appear to reduce scar formation after retinal reattachment even in patients with proliferative diabetic retinopathy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2022 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Methotrexate's Impact on COVID Vaccination: New Insights Made Methotrexate's Impact on COVID Vaccination: New Insights Made
New studies assess patients with various immune-mediated inflammatory diseases to determine the risks and benefits of pausing methotrexate after the COVID-19 vaccine.Medscape Medical News (Source: Medscape Nurses Headlines)
Source: Medscape Nurses Headlines - July 18, 2022 Category: Nursing Tags: Rheumatology News Source Type: news
Arthritis Patients Are Being Denied Methotrexate Post-Roe. Are People With Cancer Next?
Methotrexate is an important therapy for cancer and some oncologists are concerned about the potential knock-on effect of the supreme court decision on patients. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 18, 2022 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma & Source Type: news
